Do Traders Think Biocept Inc (BIOC) Can Turn Around Wednesday?

Wednesday, October 18, 2023 09:44 AM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think Biocept Inc (BIOC) Can Turn Around Wednesday?

Overall market sentiment has been down on Biocept Inc (BIOC) stock lately. BIOC receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Biocept Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BIOC!

See Full BIOC Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With BIOC Stock Today?

Biocept Inc (BIOC) stock is unchanged 0% while the S&P 500 is down -0.52% as of 4:00 PM on Tuesday, Oct 17. BIOC is unmoved $0.00 from the previous closing price of $0.51 on volume of 1,974,598 shares. Over the past year the S&P 500 is up 18.29% while BIOC is down -97.86%. BIOC lost -$50.69 per share in the over the last 12 months.

More About Biocept Inc

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. Click Here to get the full Stock Report for Biocept Inc stock.